Allergic disease in children: integrated approach: Case

This boy has multisystem atopic disease spanning all four compartments: persistent severe eczema, IgE-mediated peanut allergy with prior anaphylaxis, poorly controlled asthma, and perennial allergic rhinitis. He illustrates the atopic march reaching adolescence, and the combination of food allergy with undertreated asthma in a teenager who is reluctant to carry his autoinjector places him squarely in the highest-risk group for fatal anaphylaxis. The clinical task is to build one coordinated plan that treats the tendency, optimises each organ, secures the food-allergy safety net, and engages an adolescent who is at the developmental stage where risk-taking peaks. [5][6]

Clinical findings

The key findings are the four-organ pattern and the risk markers within it. The eczema is widespread and sleep-disrupting, indicating uncontrolled disease and a high sensitisation load. The peanut history is the defining risk: a documented anaphylaxis at three years, a persistent large skin-prick wheal, and sensitisation to Ara h 2, the stable storage protein that predicts systemic rather than cross-reactive, pollen-related allergy. The asthma is poorly controlled, with frequent short-acting bronchodilator use and two oral-steroid courses in a year, and poor asthma control in a food-allergic child is the single clearest predictor of fatal food anaphylaxis because the anaphylactic bronchospasm compounds an already twitchy airway. [6]

The candidate should articulate the problem representation: a 12-year-old with multisystem atopic disease and a prior peanut anaphylaxis, with poorly controlled asthma and adolescent barriers to autoinjector adherence, requiring an integrated plan that prioritises anaphylaxis safety, asthma control, skin control, and adolescent engagement. The candidate should also name the risk explicitly: this is a prototypical fatality-risk profile. [4]

Investigations

The peanut testing illustrates the correct interpretation of allergy tests. The 9 mm skin-prick wheal and the Ara h 2 sensitisation confirm sensitisation and, taken with the anaphylaxis history, confirm clinical allergy; but the numbers alone would not diagnose him, because the diagnosis rests on the history plus the reaction. The role of testing here is prognostic: serial specific immunoglobulin E trends guide when a supervised oral food challenge is worthwhile, and the challenge is the only test that confirms resolution. [3]

Asthma assessment adds spirometry from around five years to document reversible airflow limitation, an asthma-control score, and review of inhaler technique and adherence. Eczema needs no specific testing but a bacterial swab is taken if infection is clinically present. The rhinitis is a clinical diagnosis. The candidate should avoid indiscriminate broad food panels, which produce false positives and drive harmful over-restriction in a child whose growth and diet must be protected. [5]

Management

The integrated plan runs three lanes. The acute-anaphylaxis lane secures the safety net: a loaded adrenaline autoinjector with a dose appropriate for his weight (300 micrograms for a child this size), a written anaphylaxis action plan, and explicit engagement with the adolescent barrier to carrying it. This is the non-negotiable core of the plan, and the candidate should describe a concrete adolescent-engagement strategy: a discreet autoinjector, peer education, partner and school involvement, and screening for the anxiety that chronic anaphylaxis risk produces. [4][6]

The chronic-control lane treats each organ in parallel. Asthma is stepped up from salbutamol-only to a daily inhaled corticosteroid preventer with a single-inhaler maintenance-and-reliever regimen, a written asthma action plan, trigger control, and a biologic such as omalizumab or mepolizumab if severe disease persists; optimising asthma control is itself an anaphylaxis-safety intervention. Eczema is managed with an emollient foundation, a proactive topical corticosteroid or calcineurin-inhibitor regimen with weekend proactive therapy, treatment of infection, and dupilumab for the severe unresponsive disease he appears to have. Rhinitis is treated with an oral non-sedating antihistamine and an intranasal corticosteroid. [5]

The prevention lane is relevant for his siblings rather than for him, but it is part of the integrated family discussion: early allergen introduction from around four to six months (LEAP, NIAID addendum), with test-then-feed for the severe-eczema or egg-allergic infant. The skin-barrier nuance is worth stating explicitly: aggressive treatment of established eczema is essential, but routine neonatal emollient is not proven prevention (KEEP positive, BEEP null), so the family should not be told that moisturising a newborn sibling will prevent allergy. [1][2]

Prognosis and the shared decisions

The natural history is reassuring for the family. Peanut allergy resolves in roughly one in five children by four years, and although he has not yet resolved, serial specific immunoglobulin E trends should be tracked and a supervised oral food challenge arranged when the trend suggests it, because the challenge is the only test that confirms resolution and lifts the restriction. His asthma often improves into adolescence, and his rhinitis is a manageable chronic condition with the right therapy, so the family should be told the trajectory is toward improvement with the right plan. [3]

The oral-immunotherapy decision is the shared decision that fits this adolescent particularly well. Agents such as AR101 desensitise a majority of peanut-allergic children and adolescents, but the PACE meta-analysis confirmed a substantial burden of reactions and adrenaline use during treatment, so the trade-off is between the safety and burden of strict avoidance with an autoinjector and the desensitisation-but-reaction-burden of active treatment. For an adolescent whose chief harm is the social and psychological load of carrying and disclosing an autoinjector, the quality-of-life argument for immunotherapy may be strong, but it requires adherence to a daily dosing and escalation regimen and shared decision-making that weighs his values. [7]

The closing point for the long case is the integrated principle: one child, one tendency, one plan, one team. The candidate who presents a coordinated plan with a lead clinician, a written anaphylaxis action plan, a written asthma action plan, an eczema regimen, a rhinitis regimen, a dietitian, a plan for peanut re-challenge, an adolescent-transition pathway, and school engagement has delivered the fellowship-level answer. [5]